Orphazyme elects new board member

Andrew Mercieca has been formally appointed to the board of biotech company Orphazyme at an extraordinary general meeting.

Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix

At an extraordinary general meeting on Tuesday, biotech firm Orphazyme elected a new board member, Andrew Mercieca.

Mercieca was proposed to fill the vacancy left by Catherine Moukheibir back in December, and, until formally elected, he was also appointed observer and consultant to the board.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs